Yao Akihisa, Sejima Takehiro, Iwamoto Hideto, Masago Toshihiko, Morizane Shuichi, Honda Masashi, Takenaka Atsushi
Division of Urology, Department of Surgery, Tottori University Faculty of Medicine, Yonago, Japan.
Int J Urol. 2015 Sep;22(9):827-33. doi: 10.1111/iju.12839. Epub 2015 Jun 18.
To evaluate the prognostic significance of the neutrophil-to-lymphocyte ratio in patients receiving chemotherapy with docetaxel for castration-resistant prostate cancer.
A total of 57 castration-resistant prostate cancer patients treated between 2009 and 2014 were included in the present retrospective study. All patient data, including clinicopathological factors, were assessed. Univariate and multivariate Cox regression models were used to predict overall survival and progression-free survival after chemotherapy initiation.
The median overall survival and progression-free survival were determined as 19.0 months (range 1-61 months) and 10.0 months (range 1-56 months), respectively. The cut-off level of the neutrophil-to-lymphocyte ratio was set as the median value of 3.5 among all patients in this study. In Kaplan-Meier analysis, the median overall survival and progression-free survival were shorter in patients with a high neutrophil-to-lymphocyte ratio compared with those with a low neutrophil-to-lymphocyte ratio (15 vs 20 months, P = 0.0125; and 9.5 vs 15 months, P = 0.0132, respectively). The overall survival and progression-free survival periods in patients with a high neutrophil-to-lymphocyte ratio were significantly shorter than those of patients with a low neutrophil-to-lymphocyte ratio (P = 0.0178 and 0.0176, respectively). In the multivariate analysis, a high neutrophil-to-lymphocyte ratio was an independent predictor of overall survival and progression-free survival (hazard ratio 2.728, 95% confidence interval 1.05-7.09, P = 0.039; and hazard ratio 2.376, 95% confidence interval 1.12-5.06, P=0.024, respectively).
The present study results suggest that the neutrophil-to-lymphocyte ratio is a useful prognostic factor in patients with castration-resistant prostate cancer treated by docetaxel chemotherapy. These findings might be useful in determining treatment strategies in the future.
评估中性粒细胞与淋巴细胞比值在接受多西他赛化疗的去势抵抗性前列腺癌患者中的预后意义。
本回顾性研究纳入了2009年至2014年间接受治疗的57例去势抵抗性前列腺癌患者。评估了所有患者的数据,包括临床病理因素。使用单因素和多因素Cox回归模型预测化疗开始后的总生存期和无进展生存期。
中位总生存期和无进展生存期分别确定为19.0个月(范围1 - 61个月)和10.0个月(范围1 - 56个月)。本研究中所有患者中性粒细胞与淋巴细胞比值的临界值设定为中位数3.5。在Kaplan-Meier分析中,中性粒细胞与淋巴细胞比值高的患者中位总生存期和无进展生存期比比值低的患者短(分别为15个月对20个月,P = 0.0125;9.5个月对15个月,P = 0.0132)。中性粒细胞与淋巴细胞比值高的患者总生存期和无进展生存期显著短于比值低的患者(分别为P = 0.0178和0.0176)。在多因素分析中,高中性粒细胞与淋巴细胞比值是总生存期和无进展生存期的独立预测因素(风险比2.728,95%置信区间1.05 - 7.09,P = 0.039;风险比2.376,95%置信区间1.12 - 5.06,P = 0.024)。
本研究结果表明,中性粒细胞与淋巴细胞比值是接受多西他赛化疗的去势抵抗性前列腺癌患者有用的预后因素。这些发现可能有助于未来确定治疗策略。